Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Teleconference Memorandum - Weekly Update Telecon - Provenge, March 23, 2007


TELECONFERENCE MEMORANDUM                                                   Public Health Service
                                                                                              Food and Drug Administration
                                                                                              Center for Biologics Evaluation and Research


Date\Time: March 23, 2007

CBER Representatives: Keith Wonnacott, Stephanie Simek, Celia Witten, Boguang Zhen, Peter Bross, Kimberly Benton, Mark Davidson, Tom Finn, Ashok Batra, Lori Tull

Sponsor’s Representative: Elizabeth Smith, Mark Frohlich, Lianng Yuh, Connie Spooner, Nicole Provost, David Urdal

STN : 125197/0

Subject: Weekly update telecon


Advisory Committee

There was discussion regarding Dendreon’s slides for presentation to the advisory committee. Dendreon will submit their slides to Gail today.

  1. Cerebrovascular events for all randomized studies with treatment arms as randomized (previously submitted; as reference)
  2. Cerebrovascular events for all randomized studies with treatment arms as exposed to treatment (cross-over/salvage patients included in treatment arm rather than placebo)
  3. Cerebrovascular events for all randomized studies with sipuleucel-T, salvage and placebo broken out separately
  4. Observed time to cerebrovascular events from last infusion for all randomized studies (data from D9902B/Study 3 now included)
  5. Overall survival by cumulative CD54 upregulation quartiles along with pure placebo (Integrated Studies 1 & 2)
  6. Overall survival in salvage treated patients by CD54 upregulation quartiles (Integrated Studies 1 & 2)


  • CBER stated that there was one issue with regard to Dendreon’s response to the 483. CBER requested to see and review the data for six lots in module b(4) This data would be a major amendment to the BLA.
    • Dendreon asked if CBER would be willing to discuss other scenarios.
  • Validation for 3 lots in the facility then submit a supplement for increased capacity (b(4)), followed by an b(4)
  • CBER responded that they would be willing to consider the limited capacity. CBER would discuss this internally and then schedule another telecom with Dendreon after the advisory committee to discuss the details. CBER would also discuss the supplement pathway internally.
  • Dendreon agreed.

(N:/IOD/Tull/125197/tcons/032307_weekly tcon.doc)

Page Last Updated: 03/24/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English